ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Growing Number Of New Research Ideas Create NCI Dilemma; How to Fund Them With A Flat Budget

October 1, 1982

In Brief: Margaret Sloan, Pioneer In International Medicine Collaboration, Dies; Hammer To Address AACI

January 1, 1982

In Brief: ACOS Moves Up Schedule for TNM Staging System From 1986 To “As Expeditiously As Possible”

January 13, 1984

Gerald Murphy To Leave Cancer Society Sept. 1 To Direct Foundation

April 23, 1993

BRAF Mutation Testing Classifies Indeterminate FNA Samples

March 29, 2013

House Committee Gives NCI Only $6.5 Million Over President’s request

July 28, 1989